source
- Merck projects continued investment and growth as Keytruda patent expiresMerck reported third‑quarter results on an investor call, saying sales expectations were above forecasts thanks to strong performance of subcutaneous Keytruda and the pulmonary arterial hypertensio…
- Eli Lilly beats Q3 revenue forecasts, lifts full-year outlookEli Lilly reported third-quarter revenue of $24.4 billion, roughly $2 billion above analysts' expectations. The outperformance underscores the company's strong position, driven in part by its GLP-…